ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Purchased by Swiss National Bank

Swiss National Bank raised its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 6.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 458,400 shares of the biotechnology company’s stock after purchasing an additional 28,500 shares during the quarter. Swiss National Bank owned about 0.19% of ADMA Biologics worth $7,862,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. State Street Corp boosted its holdings in ADMA Biologics by 61.4% in the third quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock valued at $259,970,000 after acquiring an additional 4,945,063 shares during the last quarter. Perpetual Ltd purchased a new stake in shares of ADMA Biologics during the 4th quarter worth about $62,300,000. Lord Abbett & CO. LLC purchased a new stake in shares of ADMA Biologics during the 3rd quarter worth about $61,858,000. Allspring Global Investments Holdings LLC increased its position in ADMA Biologics by 1,144.4% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company’s stock worth $51,016,000 after purchasing an additional 2,613,482 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in ADMA Biologics in the fourth quarter valued at approximately $19,076,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a $25.00 price objective on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Stock Up 0.8 %

Shares of NASDAQ:ADMA opened at $19.80 on Friday. The company has a market capitalization of $4.68 billion, a price-to-earnings ratio of 70.71 and a beta of 0.60. The company has a 50 day moving average of $16.76 and a two-hundred day moving average of $18.04. ADMA Biologics, Inc. has a 52-week low of $5.90 and a 52-week high of $23.64. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.